Skip to main content
Article thumbnail
Location of Repository

doi:10.1155/2010/516768 Review Article Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions

By Shigeo Koido, Sadamu Homma, Eiichi Hara, Yoshihisa Namiki, Akitaka Takahara, Hideo Komita, Eijiro Nagasaki, Masaki Ito, Toshifumi Ohkusa, Jianlin Gong and Hisao Tajiri


Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The goal of cancer vaccines is to induce antitumor immunity that ultimately will reduce tumor burden in tumor environment. Several strategies involving dendritic cells- (DCs)- based vaccine incorporating different tumor-associated antigens to induce antitumor immune responses against tumors have been tested in clinical trials worldwide. Although DCs-based vaccine such as fusions of whole tumor cells and DCs has been proven to be clinically safe and is efficient to enhance antitumor immune responses for inducing effective immune response and for breaking T-cell tolerance to tumor-associated antigens (TAAs), only a limited success has occurred in clinical trials. This paper reviews tumor immune escape and current strategies employed in the field of tumor/DC fusions vaccine aimed at enhancing activation of TAAs-specific cytotoxic T cells in tumor microenvironment. 1. T Lymphocytes and Tumor Immunity The T-cell receptor (TCR) interaction with complex of peptides and major histocompatibility complex (MHC) molecules is a critical event in T-cell-mediated responses. The proteasomes in tumor cells degrade tumor-associate

Year: 2013
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.